Classical Hodgkin lymphoma (cHL) is unique among lymphoid malignancies in several key
biological features.(i) The Hodgkin and Reed-Sternberg (HRS) tumor cells are rare among …

Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for
the treatment of hematological malignancies. However, in patients with solid tumors …

Trogocytosis modulates immune responses, with still unclear underlying molecular
mechanisms. Using leukemia mouse models, we found that lymphocytes perform …

Trogocytosis occurs when one cell contacts and quickly nibbles another cell and is
characterized by contact between living cells and rapid transfer of membrane fragments with …

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical response in
treating both hematologic malignancies and solid tumors. Although instances of rapid tumor …

Immunotherapy has brought a paradigm shift in the treatment of tumors in recent decades.
However, a significant proportion of patients remain unresponsive, largely due to the …

Lymphoma is a common hematologic malignant tumor that originates from lymph nodes or
other lymphoid tissues. The tumor microenvironment (TME) plays an indispensable role in …

The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with
programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 …

Simple Summary Hodgkin lymphomas (HLs) include two main types, classic HL (CHL) and
nodular lymphocyte predominant HL (NLPHL). Recent molecular findings in HLs have …

Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms,
which may potentially include the programmed cell death ligand‐1 (PD‐L1): programmed …